Short Interest in Ascendis Pharma A/S (NASDAQ:ASND) Decreases By 5.5%

Ascendis Pharma A/S (NASDAQ:ASND) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 3,420,000 shares, a decline of 5.5% from the December 15th total of 3,620,000 shares. Based on an average daily trading volume, of 426,500 shares, the days-to-cover ratio is currently 8.0 days.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Bank of America boosted their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Oppenheimer reduced their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Stifel Nicolaus increased their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Finally, Wedbush restated an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $192.07.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock opened at $128.13 on Friday. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00. The firm has a market cap of $7.78 billion, a PE ratio of -15.86 and a beta of 0.65. The company has a 50 day simple moving average of $133.13 and a two-hundred day simple moving average of $133.50.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds have recently made changes to their positions in ASND. Wilmington Savings Fund Society FSB purchased a new stake in Ascendis Pharma A/S during the third quarter valued at about $30,000. GAMMA Investing LLC raised its holdings in shares of Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares in the last quarter. Pursue Wealth Partners LLC bought a new stake in Ascendis Pharma A/S in the 3rd quarter worth approximately $217,000. Finally, Rhumbline Advisers boosted its stake in Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after buying an additional 143 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.